 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
61 News |  |
| «12 |
- BI 655064 / AbbVie, Boehringer Ingelheim
New P1 trial: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Dec 10, 2013
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
- || BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment change: Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers (clinicaltrials.gov) - Dec 9, 2013
P1, N=64, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=48 --> 64
- ||| BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment open: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy (clinicaltrials.gov) - Aug 28, 2013
P1, N=106, Recruiting, Sponsor: Boehringer Ingelheim
N=48 --> 64 Active, not recruiting --> Recruiting
- ||| BI 655064 / AbbVie, Boehringer Ingelheim
New P1 trial: Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers (clinicaltrials.gov) - Aug 5, 2013
P1, N=64, Active, not recruiting, Sponsor: Boehringer Ingelheim
- ||| BI 655064 / AbbVie, Boehringer Ingelheim
New P1 trial: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy (clinicaltrials.gov) - Dec 16, 2012
P1, N=106, Recruiting, Sponsor: Boehringer Ingelheim
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial completion: Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers (clinicaltrials.gov) - Oct 16, 2012
P1, N=72, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
Active, not recruiting --> Recruiting Recruiting --> Completed
- BI 655064 / AbbVie, Boehringer Ingelheim
New P1 trial: Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers (clinicaltrials.gov) - Jan 12, 2012
P1, N=72, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals